All In MedTech

Device Trial Radar · NCT07687485

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Sep 4, 2026

Primary completion

Sep 2029

Study completion Sep 2038

Sponsor

Lead sponsor
Laplace Interventional, IncNot on our public-company list
Sponsor type
Industry
First posted
Jul 7, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical study is to assess the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of symptomatic subjects with at least severe tricuspid regurgitation (TR).

Conditions

  • Severe Tricuspid Valve Regurgitation
  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Disease
  • Cardiovascular Diseases (CVD)
  • Heart Valve Diseases
  • Tricuspid Valve Insufficiency
  • Severe Heart Valve Disease
  • Symptomatic Tricuspid Regurgitation

Interventions

  • Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR SystemDevice

    Transcatheter Tricuspid Valve Replacement

  • Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR SystemDevice

    Transcatheter Tricuspid Valve Replacement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of major adverse events (MAEs)Time frame: 30 days post-procedure
  2. Composite 12-Month Endpoint: All-cause mortality, heart failure hospitalization, tricuspid valve re-interventionTime frame: 12 months post-procedure

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Oklahoma Heart Institute

    Tulsa, Oklahoma · Recruiting

  • Ballad Health

    Kingsport, Tennessee · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.